Strategic Partners A/S
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jakob Færch Bendtsen
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Ole MaalOees Vej 3 Copenhagen Denmark 2200
- IPO Date
- Jul 16, 2019
- Website
- strategic-partners.dk
- Similar Companies
- Business
- Strategic Partners A/S operates as a Danish investment firm. The company specializes in forging strategic alliances with promising businesses, where it assumes active ownership to cultivate value through its expertise. Previously, the entity was known as Orphazyme A/S, engaged in biopharmaceutical development, before divesting its biotechnology assets in May 2022. Its transformation and name change to Strategic Partners A/S were officially implemented in October 2024. Established in 2009, the firm is headquartered in Herlev, Denmark.
Orphazyme completes sale of substantially all of its assets and business activities to KemPharm
Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.
Why Entera Bio, Orphazyme, Bellerophon Are Moving Today
Kim Stratton, CEO, resigns from Orphazyme
CytRx Highlights Orphazyme's Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C
Orphazyme closes its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe
Orphazyme announces U.S. FDA acceptance and Priority Review of New Drug Application for arimoclomol for Niemann-Pick disease Type C